These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10939899)

  • 41. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature.
    Cossaart N; SantaCruz KS; Preston D; Johnson P; Skikne BS
    Bone Marrow Transplant; 2003 Jan; 31(1):57-60. PubMed ID: 12621508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
    Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
    Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
    Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
    Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed.
    Vogl DT; Stadtmauer EA
    Bone Marrow Transplant; 2006 Jun; 37(11):985-7. PubMed ID: 16708060
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
    Schneeweiss A; Hensel M; Goerner R; Khbeis T; Hohaus S; Egerer G; Solomayer E; Haas R; Grischke EM; Bastert G; Ho AD
    Stem Cells; 2001; 19(2):151-60. PubMed ID: 11239170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose chemotherapy and allogeneic immunotherapy.
    Childs R; Srinivasan R
    Lancet; 2005 Jul 23-29; 366(9482):273-5. PubMed ID: 16039317
    [No Abstract]   [Full Text] [Related]  

  • 49. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
    Vredenburgh JJ; Madan B; Coniglio D; Ross M; Broadwater G; Niedzwiecki D; Edwards J; Marks L; Vandemark R; McDonald C; Affronti ML; Peters WP
    Bone Marrow Transplant; 2006 Jun; 37(11):1009-15. PubMed ID: 16633363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Pegase" program for evaluation of autologous stem cell transplantation in breast cancer. SFGM and PEGASE Group.
    Gisselbrecht C; Viens P; Lotz JP; Biron P; Asselain B; Maraninchi D; Roché H
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S21-3. PubMed ID: 8899164
    [No Abstract]   [Full Text] [Related]  

  • 51. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
    Grodman H; Wolfe L; Kretschmar C
    Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer.
    Carlson RW; Wheatley K
    Cancer Treat Rev; 2004 Feb; 30(1):131-7. PubMed ID: 14766131
    [No Abstract]   [Full Text] [Related]  

  • 53. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.
    Pedrazzoli P; Ferrante P; Kulekci A; Schiavo R; De Giorgi U; Carminati O; Marangolo M; Demirer T; Siena S; Rosti G;
    Bone Marrow Transplant; 2003 Sep; 32(5):489-94. PubMed ID: 12942095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
    Takahashi S; Aiba K; Ito Y; Hatake K; Nakane M; Kobayashi T; Minowa S; Shibata H; Mitsuhashi J; Tsukahara S; Ishikawa E; Suzuki R; Tsuruo T; Sugimoto Y
    Cancer Sci; 2007 Oct; 98(10):1609-16. PubMed ID: 17683514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
    Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
    Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Svane IM
    Ugeskr Laeger; 2004 Nov; 166(46):4148-50. PubMed ID: 15565849
    [No Abstract]   [Full Text] [Related]  

  • 59. [Ovarian cancer treated with very-high-dose chemotherapy and peripheral hematopoietic stem cell transplantation].
    Liu K; Cui H; Qian H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):122-4. PubMed ID: 10682432
    [No Abstract]   [Full Text] [Related]  

  • 60. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
    Lotz JP; Curé H; Janvier M; Asselain B; Morvan F; Legros M; Audhuy B; Biron P; Guillemot M; Goubet J; Laadem A; Cailliot C; Maignan CL; Delozier T; Glaisner S; Maraninchi D; Roché H; Gisselbrecht C
    Eur J Cancer; 2005 Jan; 41(1):71-80. PubMed ID: 15617992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.